Celldex Therapeutics Advances Barzolvolimab Research with Promising Results in Atopic Dermatitis and Urticaria
HAMPTON, N.J. Dec. 19, 2024 In a significant stride for dermatological therapeutics, Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced the initiation of a Phase 2 study for barzolvolimab, aimed at addressing the debilitating effects of atopic dermatitis (AD). Concurrently, the company celebrated notable achievements in its ongoing research on chronic spontaneous urticaria and chronic inducible urticaria, underscoring the versatility and potential of barzolvolimab in treating mast cell-related conditions.
Atopic dermatitis remains a prevalent chronic inflammatory skin disease, affecting up to 20% of the U.S. population at some point in their lives. The disease significantly impairs quality of life due to its chronic nature and the diverse symptoms it presents, such as intense itching and inflammation. Mast cells play a pivotal role in the pathophysiology of AD, contributing to epithelial barrier dysfunction, immune cell recruitment, neuroinflammation, and other disease-related processes. These findings spotlight the potential of barzolvolimab, a humanized monoclonal antibody, which effectively targets and inhibits the receptor tyrosine kinase KIT crucial for mast cell function and survival.
Celldex’s bold venture into AD treatment follows groundbreaking results from barzolvolimab trials in other mast cell-mediated conditions. Earlier in December, the company highlighted a landmark achievement during the 52-week Phase 2 study of barzolvolimab in chronic spontaneous urticaria (CSU) presented at the European Academy of Dermatology and Venereology (EADV) 2024. An impressive 71% of patients receiving 150 mg of barzolvolimab every four weeks achieved a complete response by Week 52. The study revealed rapid, profound, and durable improvement in Urticaria Activity Score (UAS7) as early as the first week, with sustained response across different patient groups, including those experienced with omalizumab or refractory to previous treatments. The trial confirmed barzolvolimab s profile as well-tolerated over the year-long study, suggesting significant promise for patients who have previously had limited treatment options. The company is now gearing towards enrollment in global Phase 3 CSU trials, reflecting their commitment to expanding therapeutic solutions for urticaria sufferers worldwide.
In addition to CSU, Celldex unveiled positive topline results from their Phase 2 study of barzolvolimab in chronic inducible urticaria (CIndU), comprising cold urticaria (ColdU) and symptomatic dermographism (SD). These subtypes of urticaria are characterized by symptom triggers cold exposure in ColdU and physical pressure in SD which manifest as hives or wheals unresponsive to conventional antihistamine treatments. The promising results further emphasize barzolvolimab s dual role in inhibiting the KIT receptor, thereby controlling mast cell activation and reducing symptom prevalence.
Through these clinical trials, Celldex is setting a new benchmark for the treatment of conditions intricately linked to mast cell dysfunction. The progressive data emerging from Celldex s studies not only enhance the prospects for effective AD therapy but also for a new generation of treatments addressing a broad spectrum of mast cell-associated disorders. With barzolvolimab at the helm of this endeavor, Celldex continues to unlock novel avenues for enhancing patient quality of life.
Comments